|
Genetics of Rheumatoid Arthritis Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Genetics of Rheumatoid Arthritis conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Genetics of Rheumatoid Arthritis Clinical research trials and Genetics of Rheumatoid Arthritis health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Genetics of Rheumatoid Arthritis. Genetics of Rheumatoid Arthritis Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Genetics of Rheumatoid Arthritis clinical trial. Test subjects typically receive the most expert healthcare available for their Genetics of Rheumatoid Arthritis condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetics of Rheumatoid Arthritis  Genetics of Rheumatoid Arthritis
Genetics of Rheumatoid Arthritis
For Condition: Rheumatoid Arthritis
Status: No longer recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: This study attempts to identify the genes responsible for rheumatoid arthritis (RA), or inflammation of the joints. It is known that genes play an important role in RA, but their number and significance have not been determined. RA tends to run in families. This study will examine the DNA (hereditary material) of patients with RA and their family members to try to determine which chromosomes(s) contain the genes responsible for the disease. Patients with rheumatoid arthritis and their family members may be eligible for this study. Participants with RA who have a brother or sister with RA will undergo the following procedures: -Review of their medical records -Medical history -Examination of the joints -Hand X-rays -Blood tests Participants who 1) do not have RA but who have a relative with the disease, or 2) have RA and a relative other than a brother or sister who has the disease will provide a blood sample or a buccal (cheek) cell sample. Cheek cells are obtained by swishing a small amount of mouthwash in the mouth or by lightly bushing the inside of the cheek with a swab or brush. The samples will be tested for rheumatoid factor, DNA studies, and HLA type (a blood type found on white blood cells). Certain HLA types have been associated with an increased risk or severity of RA.
Details: The purpose of this protocol is to identify genetic susceptibility loci for rheumatoid arthritis. The Rheumatic Disease Genetics and Genomics Branch of the Intramural Research Program of NIAMS has joined with several Extramural Centers to form the North American Rheumatoid Arthritis Consortium (NARAC). The Consortium intends to identify and obtain clinical specimens on a total of 1000 sibling pairs with rheumatoid arthritis; up to 100 sibling pairs will be recruited at the Clinical Center. Samples from parents and other family members will also be obtained, where appropriate. Rheumatoid factors, HLA-DR typings, and hand films will be obtained on all sibling pairs. In addition, DNA will be extracted from peripheral blood or buccal scrapings. The DNA from all 1000 sibling pairs will be typed for a set of approximately 350 genetic markers in order to identify chromosomal regions likely to harbor genes conferring susceptibility to rheumatoid arthritis. For those chromosomal regions that are positive in this initial screen, families will be genotyped for additional markers to define disease-associated haplotypes. Candidate genes in the regions of interest may also be screened for mutations in rheumatoid arthritis patients. Moreover, it is expected that this protocol will define the candidate regions to be explored in future rheumatoid arthritis positional cloning projects.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: SIBLING PAIR: A diagnosis of rheumatoid arthritis in both sibs by the 1987 ACR criteria. Definite bony erosions in at least one affected sibling. Age of disease onset greater than 18 years and less than 60 years in at least one sibling. Neither sibling has psoriasis, inflammatory bowel disease, or systemic lupus erythematosus. BLOOD RELATIVES OF AFFECTED SIBLING PAIRS: Age greater than 18 years. Where possible, all other affected siblings will be invited to participate. Where possible, both parents of affected siblings will be invited to participate. Other relatives, both affected and unaffected, may be invited to participate if, in the opinion of the investigators, samples from these individuals would contribute important genetic information. Two cases in which this might happen are: a) extended families in which there are several affected individuals, where conventional linkage analysis might be applied; b) affected sibling pairs for which parents are unavailable, where additional siblings will provide information on parental alleles not transmitted to the affected siblings. EXCLUSION CRITERIA FOR AFFECTED SIBLINGS: Psoriasis, inflammatory bowel disease, systemic lupus erythematosus. Inability to provide infomed consent. The sole criterion for exclusion of adult blood relatives of affected sibling pairs would be inability to provide informed consent.
Total Enrollment: 999
Location and Contact Information:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 980124; 98-AR-0124
Study Start Date: July 7, 1998
Record last reviewed: June 10, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001678
Other Rheumatoid Arthritis Studies:
1. Long term safety and tolerability of an investigational drug in patients with rheumatoid arthritis
2. Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
3. Literacy in Arthritis Management
4. A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects with Active Rheumatoid Arthritis
5. A multi-center trial to compare the efficacy and safety of three doses of Meloxicam and placebo in patients with Rheumatoid Arthritis.
Related Studies:
Other Rheumatoid Arthritis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Genetics of Rheumatoid Arthritis
|
|
|
|
|
|
|
|
